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SUMMARY 
 
Placebo-controlled trials have shown that vitamin C supplementation decreases the duration and 
severity of common cold infections. However, the magnitude of the benefit has substantially varied, 
hampering conclusions about the clinical significance of the vitamin. In this paper, 23 studies with 
regular vitamin C supplementation (?1 g/day) were analyzed to find out factors that may explain some 
part of the variation in the results. It was found that on average, vitamin C produces greater benefit for 
children than for adults. The dose may also affect the magnitude of the benefit, there being on average 
greater benefit from ?2 g/day compared to 1 g/day of the vitamin. In five studies with adults 
administered 1 g/day of vitamin C, the median decrease in cold duration was only 6%, whereas in two 
studies with children administered 2 g/day the median decrease was four times higher, 26%. The trials 
analyzed in this work used regular vitamin C supplementation, but it is conceivable that therapeutic 
supplementation starting early at the onset of the cold episode could produce comparable benefits. Since 
few trials have examined the effects of therapeutic supplementation and their results have been variable, 
further therapeutic trials are required to examine the role of vitamin C in the treatment of colds. 
 
 
 
INTRODUCTION 
 
In placebo-controlled studies, regular vitamin C supplementation (?1 g/day) has consistently decreased 
morbidity due to the common cold (1-8). While the biochemical basis of this effect is not well 
understood, vitamin C does have diverse effects on the immune system (3,5,9). 
Since the magnitude of the benefit has varied substantially in the controlled trials, the clinical 
significance of vitamin C in common cold therapy remains an open question. The purpose of the present 
work was to investigate whether factors can be identified to explain some part of the variation in the 
results of the controlled trials. The particular questions addressed in the present analysis were whether 
dose-dependency can be seen in high vitamin C doses, and whether the effect depends on the 
characteristics of subjects. 
 
3 
METHODS 
 
Since the literature on vitamin C common cold studies has previously been thoroughly surveyed 
(4,10,11), the older literature was not searched anew. The previous searches were extended by 
MEDLINE searches to identify newer vitamin C-common cold trials. All placebo-controlled studies 
using regular vitamin C supplementation with ?1 g/day of the vitamin were selected for the present 
quantitative analysis (12-31), and the results are shown in Table 1. Regular supplementation refers here 
to initiating supplementation with healthy people and continuing over the occurring common cold 
episodes. For a concise summary of the original results, see ref. 3. The Anderson 1974 study (17) with 
adults is excluded from Table 1, since there is evidence of biased distribution of subjects in the eight 
study groups (5,17). The Carson 1975 study (20) with adults administered 1 g/day is excluded, since the 
authors were interested solely in the possibility of there being an effect on the incidence of colds, and 
not on the severity of symptoms, so that appropriate data are not available. The results of the Karlowski 
1975 study (22,32) were recently reanalyzed (7), and the linear trend in their results has been analyzed 
in this work (Table 2) with the analysis of variance (34). All the studies with children used 
schoolchildren as subjects. The total number of subjects in the studies in Table 1 was over 6100. All 
studies except one (14) were double-blind. Some of the placebo groups were given 10–70mg/day of 
vitamin C to ensure that the effects of the larger dose were not due to the alleviation of a true dietary 
deficiency (25,26,28,30). The Relative Effect on the severity of common cold episodes in the vitamin C 
groups relative to the placebo groups was calculated for each study as the difference between the 
outcomes in the vitamin C and placebo group divided by the outcome in the placebo group (Table 1). 
Pooled confidence intervals for the four groups were not calculated since in several studies standard 
error and standard deviation were not reported. The discussion of therapeutic trials is also restricted to 
studies that employed ?1 g/day of vitamin C (22,35-40). 
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THE COMMON COLD STUDIES 
 
To estimate the magnitude of the benefit of vitamin C supplementation on common cold symptoms, all 
placebo-controlled trials with regular supplementation (?1 g/day) were searched. The Relative Effect of 
vitamin C on the severity of cold episodes for each outcome was calculated (Table 1). In some studies, 
2–3 outcome parameters were measured to quantify the duration or severity of episodes, the results on 
different parameters occasionally differing considerably. For the present analysis, we selected the 
outcome seemingly most important for the patient, such as days of absence from work or school, or days 
in bed, when several parameters were measured in the study. Nevertheless, in such cases the effect on 
the duration of symptoms is still shown in parenthesis in Table 1. 
In order to analyze the dose-dependency of vitamin C intake, the trials were divided into those 
using 1 g/day and those using ?2 g/day. Furthermore, as the weight and/or age of the subjects can 
modify the effect of a fixed dose, the studies with children were concurrently separated from the studies 
with adults (Table 1). Finally, because three of the adult trials used military recruits who are highly 
atypical representatives of the general adult population, these three trials were segregated from the other 
adult studies (Table 1). 
The mean Relative Effect was calculated for the four groups of trials in Table 1, excluding the 
soldier trials, using the number of episodes in the vitamin C group as the weight, thereby giving more 
precise results greater weight in calculating the mean (Table 1). The resultant mean Relative Effect 
values have been plotted in Figure 1 as a function of vitamin C dose. Assuming that the mean Relative 
Effect is a valid estimate for each of the four groups, the results suggest that larger doses (?2 g/day) 
produce a greater benefit than small doses (1 g/day) for both adults and children. 
The assumption that the dose-dependency is linear allows crude extrapolation of doses that could 
possibly decrease the severity of cold episodes by half (Fig. 1). For children and adults respectively 3.9 
and 10 g/day of vitamin C would yield Relative Effect = –50%. However, in the case of children there 
are only two rather small trials in the high dosage group, and there is a great variation in the results of 
the low dosage trials (Table 1). In the case of adults, two trials with high dosages used induced 
rhinovirus infection (16,31), and one trial found a great divergence in two different outcomes (13). The 
evidence for dose-dependency is thus not strong in Figure 1. Still, as children on average weigh 
considerably less than adults, the difference between them is also consistent with the notion that a higher 
dose per unit of weight produces a greater benefit at the dosage levels studied so far. 
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Table 1. The effect of regular vitamin C supplementation (?1 g/day) on common cold severity and duration 
Study (Ref.) No. of episodes in 
vitamin C group 
Dose 
(g/day) 
Relative effect 
(%) 
Outcome 
Adults     
1 g/day during the cold episode     
Clegg & Macdonald 1975 (21) 68 1 ?5.3 Duration of symptoms 
Briggs 1984 (30) 125 1 ?6.1 Duration of symptoms 
Elwood et al 1976 (24) 627 1 ?6.4 Duration of symptoms 
Clegg & Macdonald 1975 (21) 51 1 a ?7.9 Duration of symptoms 
Charleston & Clegg 1972 (14) 44 b 1 ?17 Duration of symptoms 
Total no. episodes 915 1 ?6.9 Mean 
   ?6.4 Median 
?2 g/day during the cold episode     
Karlowski et al 1975 (7,22,32) 52 3 ?6.0 Duration of symptoms 
Karlowski et al 1975 (7,22,32) 76 3 + 3 c ?17 Duration of symptoms 
Anderson et al 1972 (13) 561 1 + 3 c ?21 Days confined to house 
   (?5.3) Duration of symptoms 
Schwartz et al 1973 (16) 11 d 3 ?30 Severity of symptoms e 
Mink et al 1988 (31) 4 d 2 ?50 Severity of symptoms 
Total no. episodes 704 4.1 ?20 Mean 
   ?21 Median 
Schoolchildren     
1 g/day during the cold episode     
Carr et al 1981 (28) 94 f 1 +6.3 Severity of symptoms 
   (+0.7) Duration of symptoms 
Coulehan et al 1976 (23) 98 1 ?5.2 Duration of symptoms 
Coulehan et al 1974 (18) 19 1 ?12 Duration of symptoms 
Ludvigsson et al 1977 (26) 225 1 ?14 Absence from school 
   (?5.9) Duration of symptoms 
Miller et al 1977 (25) 53 1 ?20 Days in bed 
   (?7.2) Duration of symptoms 
Ritzel 1961 (1,2,12,33) 17 1 ?29 Duration of symptoms 
Ludvigsson et al 1977 (26) 22 1 ?31 Absence from school 
   (?39) Duration of symptoms 
Carr et al 1981 (28) 57 g 1 ?35 Severity of symptoms 
   (?35) Duration of symptoms 
Total no. episodes 585 1 ?13 Mean 
   ?17 Median 
?2 g/day during the cold episode     
Bancalari et al 1984 (29) 38 2 ?24 Duration of symptoms 
Coulehan et al 1974 (18) 16 2 ?29 Duration of symptoms 
Total no. episodes 54 2 ?26 Mean 
   ?26 Median 
Military recruits     
Pitt & Costrini 1979 (27) 600 2 ?5.1 Severity of symptoms 
   (?2.6) Duration of symptoms 
Sabiston & Radomski 1974 (19) 6 1 ?67 Duration of constitutional symptoms h 
   (?25) Duration of nasal symptoms 
Elliott 1973 (15) 37 i 2 ?72 Days of sore throats 
   (?69) Days of productive coughs 
 
Notes to Table 1: The mean Relative Effect and the mean dose were calculated using the number of episodes in the vitamin C 
group as the weight. The differences in outcomes indicated by parentheses are not included in the calculations. 
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a 1 g/day of D-isoascorbic acid; 
b Single-blind study (all the other studies in the table are double-blind studies); 
c At the onset of a cold episode an additional 3 g/day was given for 3?5 days; in the present analysis, 4 and 6 g/day are 
regarded as the doses corresponding to the observed effects. 
d Induced rhinovirus infection; 
e Severity of symptoms on the 4th day of infection;   
f Twins living together; 
g Twins living apart; 
h Constitutional symptoms: headache, chills and fever, general malaise, nausea or vomiting; 
i The explicit number of colds was not reported; the number of subjects in the vitamin C group is 37. 
 
 
 
 
 
 
Several factors have varied between the trials, such as the characteristics of subjects, the types of 
infecting viruses, the geographic location, etc. The dietary vitamin C intake by the control group may 
also affect the differences between the vitamin and placebo groups, but the dietary intake has not been 
estimated at all in most trials. The definition of outcome has varied greatly and in several trials there has 
been a smaller effect on the duration but a larger effect on the severity of colds (13,19,25-27). Such 
factors, along with random variation, can explain a large part of the differences between the results, 
hampering the comparison of the studies. 
In two trials (18,22) different vitamin C doses were given to separate groups within the same 
study. Because of the similarity of subjects and the constant outcome definition across the study groups, 
these two trials are more pertinent to the question of dose-dependency than the comparison of means of 
dissimilar studies. Karlowski et al (22) examined the effect of 3 and 6 g/day of vitamin C on adults, and 
Coulehan et al (18) examined the effect of 1 and 2 g/day on children (Fig. 2). Extrapolation from the 
results of Coulehan et al suggests that 3.5 g/day would decrease the duration of cold episodes by half, 
consistent with the estimate derived from all studies with children. 
Karlowski et al’s results suggest that 18 g/day would decrease the duration of episodes by half 
(Fig. 2). Finally, Karlowski et al reported the standard errors of the mean duration of episodes for their 
four study groups (Table 2). The linear trend in their study groups can consequently be analyzed by the 
analysis of variance. The linear trend explains a significant part of the differences between the groups, 
whereas the remaining non-linear differences are easily explained by random variation (Table 2). The 
results of the Karlowski study are the most unambiguous evidence so far indicating that there is dose 
dependency in the >1 g/day region. 
Three of the adult trials used military recruits as subjects, and there is extreme variation in their 
results. Two of these trials (15,19) found the greatest benefit among all the 1 g/day and ?2 g/day studies, 
whereas the third (27) found the smallest benefit among all the ?2 g/day studies (Table 1). The trials 
reporting the great benefit were carried out in a special exercise during the wintertime in northern 
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Canada (19) and with the crew on a submarine (15). The Pitt and Costrini study reporting the minor 
benefit was carried out in a training camp in South Carolina (27). In the latter trial, the subjects were on 
average sick 36% (20/56) of the study days (27,41). The subjects have usually been sick less than 10% 
of the study days (3), as in the large-scale trial with adults by Anderson et al (13), where it was 7% 
(6/90). Because of the exceptional conditions in the Pitt and Costrini study it is not clear to what extent 
their results can be generalized to other circumstances. Thus, the substantially greater benefit found in 
the other two trials with military recruits (15,19) might be caused by differences in the experimental 
conditions. It is possible that specific circumstances for example in accommodation (41) and in training 
conditions are important factors affecting the role of vitamin C in military recruits. 
 
 
Table 2. Test for linear trend in Karlowski’s results (22) 
 
Group Vitamin C 
(g/day) 
c No. of 
episodes 
Duration of episodes (days) 
Mean SE Var 
0 0 1 65 7.14 0.46 13.75 
1 3 0 56 6.46 0.39 8.52 
2 3 0 52 6.71 0.53 14.61 
3 6 ?1 76 5.92 0.40 12.16 
   249    
Analysis of variance for trend 
 DF SS MS F P 
Between groups 3 54.4    
   linear 1 52.1 52.1 4.25 0.040 
   non-linear 2 2.3 1.1 0.093 0.91 
Within groups 245 3005.7 12.3   
Total 248 3060.1    
 
 
Notes to Table 2: c indicates the contrast used in the calculation of the linear trend. Variance (Var) was 
calculated from the standard error (SE) and the number of episodes (32). Group 1 was administered 
vitamin C for 5 days during colds, whereas group 2 was administered vitamin C each day during the 
study. Group 3 received vitamin C both ways. 
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Fig. 1 The effect of vitamin C dosage on the severity of common cold episodes. The mean Relative 
Effect on severity values for schoolchildren (?) and adults (?) was taken from Table 1. Linear regression 
analysis was used to extrapolate the dose producing Relative Effect = –50%. The regression lines were 
forced through Relative Effect = 0% at 0 g/day of vitamin C since such a dose must equal placebo. 
 
 
 
 
 
Fig. 2 The effect of vitamin C dosage on the duration of common cold episodes in the Coulehan 1974 
and Karlowski 1975 trials. The Relative Effect on severity values are taken from Table 1 for the 
Coulehan 1974 study (?) and the Karlowski study (?). Karlowski et al (22,32) also had a therapeutic 
group which was administered 3 g/day of vitamin C for 5 days during cold episodes and for this group 
Relative Effect = –9.5% (Table 2). In this figure, it is assumed that there is no meaningful difference 
between the regular and therapeutic supplementation and therefore the Karlowski results are plotted on 
the basis of total vitamin C dosage during the cold episodes (c.f. Table 2). 
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DISCUSSION 
 
The effect of vitamin C on the common cold has been studied quite extensively since the early 
1970s when Linus Pauling, a dual Nobel laureate, wrote a popular book on the topic suggesting that, in 
gram doses, the vitamin would substantially decrease morbidity due to the common cold (1). Although 
in further trials the benefit was not as great as Pauling had concluded from the early studies, the duration 
and severity of common cold has consistently been lower in vitamin C groups indicating a physiological 
effect (Table 1). 
In his quantitative analysis, Pauling (2) based his estimation of benefit on a single trial carried out 
by Günther Ritzel in the early 1960s with schoolboys in a skiing camp in the Swiss Alps (12,33). 
However, the conditions at a skiing camp are highly exceptional and later studies with children have 
mostly found smaller effects (Table 1). Moreover, Pauling did not restrict his estimate to children, and it 
appears that the extrapolation of Ritzel’s results to adults was among the reasons for the great 
discrepancy between Pauling's quantitative conclusions (2) and the effects seen in later studies carried 
out largely with adults (Table 1; see also ref. 8). 
The magnitude of the benefit from vitamin C supplementation is an important issue in evaluating 
the clinical significance of the vitamin in common cold therapy, even though it is unrealistic to assume 
that a single estimate of benefit would be valid for all subjects. A major problem in the comparison of 
the studies is the great variation in the outcomes between trials. For example, in the control group of 
Miller’s study (25) the mean duration of ‘days in bed’ was 1.0, whereas in Ludvigsson’s control group 
(26) the mean duration of ‘symptoms present’ was 14 days. Since it is obvious that such outcomes and 
their arithmetical differences between vitamin C and placebo groups are not comparable between 
different studies, the present analysis was based on the relative effect on outcomes, which are more 
comparable between studies. Although severity and duration may appear to be independent outcome 
parameters, the duration may largely be considered as a way of estimating the severity of episodes. This 
is most evident in the case of days of absence from school or work, or days in bed, which clearly depend 
on the severity of symptoms. 
The published trials indicate that the effect of a given vitamin C dose is on average greater for 
children than for adults (Table 1, Fig. 1). This difference may be largely due to the smaller weight of 
children, i.e. a greater dose per unit of weight, but it is possible that there also are age-dependent 
physiological differences. Furthermore, there is evidence of dose-dependency in both children and 
adults (Figs 1 & 2, Table 2). Accordingly, even though the median decrease in duration by 1 g/day can 
be considered clinically insignificant in adults (–6%; Table 1), this may be an underestimate of the 
potential benefits of higher doses, particularly when given to children. For children the median decrease 
with 2 g/day of vitamin C was four times higher (–26%). Finally, as the results of the trials are mean 
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values for a group of children, it is obvious that vitamin C is much more (and much less) beneficial for 
some individual children than is suggested by the result of a single study, or by the median of a group of 
studies. 
It is noteworthy in Table 1 that only 22% (639/2901) of all cold episodes were observed in studies 
with children and the 2 g/day studies with children cover only 2% (54/2901) of all episodes. Thus, if a 
weighted general mean is calculated for all results in Table 1, there is heavy domination by the adult 
studies, which have mostly found only a slight benefit. Consequently, such a general estimate would 
completely hide the possibility of there being a worthwhile benefit in children. 
In two studies with children, the vitamin C level in plasma (18) and urine (25) increased in 
subjects given a placebo (sic!) suggesting that tablets were exchanged by playful children. In this 
respect, the study by Carr et al (28) is interesting inasmuch as a marked benefit was observed in twins 
living apart, but no benefit in twins living together (Table 1), who apparently exchanged the tablets to a 
great extent - not so easy for twins living apart. It is thus possible that some of the published results 
underestimate the true physiological effects because of technical shortcomings in the studies. 
Linear extrapolation suggests that 4 g/day can on average reduce the severity of cold episodes by 
half in children, and 10–18 g/day may produce a similar effect in adults (Figs 1 & 2). Obviously, these 
estimates are imprecise and should be interpreted highly cautiously, but it seems probable that the doses 
used in the placebo-controlled trials (?2 g/day for children; ?6 g/day for adults) have not been large 
enough to demonstrate the maximum effect of vitamin C supplementation (Figs 1 & 2). Several 
physicians have used vitamin C in the treatment of the common cold (42-50). Bee (47) proposed 10–15 
g/ day for treating colds, and Cathcart (48,49) suggested that the optimum dose may be over 30 g/day. It 
is noteworthy that extrapolation with the data from the adult studies yields estimates crudely of the same 
magnitude (Figs 1 & 2). 
The quantitative analysis in the present work was based on studies using regular vitamin C 
supplementation, and it is important to consider whether the resultant estimates may be extrapolated to 
therapeutic doses administered after an episode occurs. This is an important question, since regular 
supplementation is more costly and cumbersome. Although vitamin C is safe even when consumed at 
high levels of intake for long periods of time (51-54), any potential harm is even less with short-term 
supplementation during common cold episodes. 
Two research groups compared the effect of therapeutic and regular vitamin C supplementation on 
colds. Karlowski et al (22) and Anderson et al (13,35) found that the estimates derived from regular 
supplementation do not overestimate the benefit of a 5-day therapeutic regime (7), suggesting that the 
estimates in Figure 1 may crudely apply to appropriate therapeutic supplementation. A few other trials 
have examined the role of therapeutic regimes, some reporting benefit from vitamin C (36-38), while 
some others found no effect (37-40). 
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In therapeutic trials, there are additional sources of technical variation when compared to regular 
supplementation studies. In the latter type of study, the vitamin is given over the entire cold episode. In 
the therapeutic trials, however, both a delay in the initiation of the treatment, and an inappropriately 
short treatment period might decrease the benefit. The former effect was observed in one of the 
therapeutic trials (36), and the latter effect may explain the inefficacy of vitamin C in three therapeutic 
trials in which supplementation lasted for only 2–3 days while the mean duration of cold episodes was 
5–8 days (37-39). Finally, it is noteworthy that none of the published therapeutic trials used children as 
subjects, whereas the regular supplementation studies have on average found a considerably greater 
benefit for children (Table 1, Fig. 1). Vitamin C is a cheap substance and safe even in large doses (51-
54). It would seem worthwhile to carry out well-planned therapeutic trials to obtain better quantitative 
estimates of the optimum doses and maximum therapeutic effects, and to better understand the potential 
differences between various groups of people. It also seems worthwhile to consider carefully the most 
relevant outcomes, as the effect on severity has often been greater than the effect on duration of 
symptoms. 
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